DREADDs
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
FTY720 hydrochloride (HB3899)
Description:Sphingosine 1-phosphate (S1P) receptor (S1P1, S1P3, S1P4, and S1P5) modulator
Purity:>98%
-
Haloperidol hydrochloride (HB1842)
Description:Dopamine receptor antagonist with partial D2-like selectivity
Purity:>99%
-
Iperoxo (HB9785)
Description:Potent muscarinic acetylcholine receptor superagonist. Also binds the hM3R-miniGq receptor.
- Description:
Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Water soluble.
Purity:>98%
-
LIH383 (HB9242)
Description:Potent and selective ACKR3 (CXCR7) agonist. Potentiates opioid peptide activity.
-
LUF7487 (HB9585)
Description:Novel, covalent Affinity-Based Probe (AfBP). Clickable antagonist for the A2AR.
- Description:
Novel, intracellular covalent chemokine CCR2 negative allosteric modulator (NAM). Binds irreversibly.
